133427-07-3

Usage

Uses

Imidazo[1,2-a]pyridine-8-carboxylic acid methyl ester HCl

Upstream product

• 107-20-0 2-chloroethanal 
• 14667-47-1 methyl 2-aminonicotinate 
• 7440-44-0 pyrographite 
• 67-56-1 methanol 
• 133427-08-4 H-imidazo[1,2-α]pyridine-8-carboxylic acid 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 24517-64-4 2-amino-3-pyridinecarbonitrile 
• 136117-70-9 8-imidazo<1,2-a>pyridinecarbonitrile 
• 133603-12-0 1,1-diethoxyethyl bromide 

Downstream Products

• 885276-95-9 3-iodo-imidazo[1,2-a]pyridine-8-carboxylic acid methyl ester 
• 1300022-42-7 3-(4-fluorophenyl)-imidazo[1,2-a]pyridine-8-carboxylic acid 
• 111477-17-9 8-hydroxymethylimidazo[1,2-a]pyridine 
• 167883-99-0 8-(chloromethyl)-imidazol[1,2-a]pyridine 
• 1446321-39-6 2-(imidazo[1,2-a]pyridin-8-ylmethoxy)-5-methoxybenzaldehyde 
• 133427-08-4 H-imidazo[1,2-α]pyridine-8-carboxylic acid 
• 136117-74-3 8-imidazo<1,2-a>pyridinecarboxaldehyde 

Relevant academic research and scientific papers

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

Nicotinamide derivatives useful as PDE4 inhibitors

This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Novel compounds

This invention relates to nicotinamide derivatives of general formula (I): in which R1, X, Y, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Condensed heterocyclic compounds, their production and use

A condensed heterocyclic compound of the general formula: STR1 wherein Q is a condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted, X is a hydrogen atom or a group attached through C, O, S or N, and Y is an electron attractive group, or its salt which is useful as agricultural chemical.

Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives

A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.